Effects of Liposomal Encapsulation on Calcium Powder Absorption and Metabolism
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Hematology Test
Study Overview
Brief Summary
Compared with traditional calcium supplements, liposome calcium can increase the bioavailability of calcium and reduce the waste caused by gastric acid destruction of calcium. This allows calcium to be released slowly in the intestines, reducing the risk of indigestion or other side effects caused by excessive intake at one time. Liposomal calcium can be taken orally directly. It does not need to be dissolved in water before taking like other calcium supplements, making it more convenient to use. Based on the above advantages, liposomal calcium is a relatively safe and easy-to-absorb calcium supplement, suitable for long-term use, and can meet the body's demand for calcium. According to the recommendations of the World Health Organization, the daily calcium intake for adults should be 1000-1300 mg. In Taiwan, the seventh edition of the revised reference intake of dietary nutrients for Chinese people recommends that the daily intake for adults should be 1,000 mg. The calcium dose used in this study was 500 mg. The purpose was to explore whether the sustained-release characteristics of liposome coating technology can improve the absorption rate after consuming calcium powder and achieve better bioavailability. It is expected that microlipids made by lecithin can Lipid calcium powder increases its maintenance time in the blood, thereby increasing the supplementary effect of calcium, and is an alternative to calcium supplements.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 20 Years to 60 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Adults aged 20-60 years old, without heart, liver, kidney, endocrine or major organic diseases (patient report), and able to fully cooperate with the experiment.
Exclusion Criteria
- •Patients with renal insufficiency and dialysis
- •Cancer patients
- •Underweight (BMI#17) or obese (BMI#27)
- •Those taking medications for chronic diseases
- •Blood pressure systolic blood pressure # 130 mmHg or diastolic blood pressure # 85 mmHg
- •Fasting blood glucose # 100 mg/dL
- •Fasting triglycerides # 150 mg/dL, total cholesterol # 200 mg/dL
- •Have a history of vitamin C allergy
- •People suffering from mental illness
- •Pregnant and breastfeeding women
- •Patients with hemosiderosis
- •Kidney stone patients
- •Supplements for those who take calcium for a long time
Arms & Interventions
Stage 1
Day 14
Intervention: Stage 1 (Dietary Supplement)
Stage 2
Day 28
Intervention: Stage 2 (Dietary Supplement)
Outcomes
Primary Outcomes
Hematology Test
Time Frame: Day 14 and 28
Fasting blood glucose, triglycerides, total cholesterol, Blood urea nitrogen, Creatinine(Blood urea nitrogen (BUN) and creatinine tests can be used together to find the BUN-to-creatinine ratio (BUN:creatinine). A BUN-to-creatinine ratio can help your doctor check for problems, such as dehydration, that may cause abnormal BUN and creatinine levels.), GOT, GPT
General examination
Time Frame: Day 14 and 28
BMI(Body Mass Index is a simple calculation using a person's height and weight. The formula is BMI = kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared) and blood pressure
Secondary Outcomes
No secondary outcomes reported
Investigators
YenPing, Lei
Assistant professor
National Yang Ming Chiao Tung University